Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.34 |
| ▸ | CDK9 | P50750 | 3/20 | 0.34 |
| ▸ | CCR3 | P51677 | 5/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804035 | 0.87 | HTR2A (0.34) | HTR2AKCNH2HTR2CDRD2CARM1 | |
| SCHEMBL12510265 | 0.83 | NPC1 (0.32) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL13286269 | 0.82 | HTR2A (0.35) | HTR2AKCNH2HTR2CDRD2CCNT1 | |
| SCHEMBL804017 | 0.81 | HTR2A (0.34) | HTR2AKCNH2HTR2CDRD2CCNT1 | |
| SCHEMBL13285903 | 0.80 | ESR1 (0.33) | HTR2AKCNH2HTR2CDRD2CCR3 | |
| SCHEMBL13285988 | 0.80 | TLR9 (0.37) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL803802 | 0.79 | BCHE (0.36) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL771442 | 0.79 | PARP1 (0.48) | HTR2AKCNH2HTR2CDRD2CCNT1 | |
| SCHEMBL84762 | 0.78 | MAOA (0.33) | HTR2AKCNH2HTR2C | |
| SCHEMBL804157 | 0.77 | HTR2A (0.33) | HTR2AKCNH2HTR2CDRD2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | HTR2A 4863/4885KCNH2 3813/4885HTR2C 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.